STAVUDINE by Cipla is 12. Approved for human immunodeficiency virus (hiv)-1 infection [see ]. First approved in 2009.
Drug data last refreshed 19h ago
12.1 Mechanism of Action Stavudine is an antiviral drug [see ]. 12.3 Pharmacokinetics The pharmacokinetics of stavudine have been evaluated in HIV-1-infected adult and pediatric patients (, , and ). Peak plasma concentrations (C max ) and area under the plasma concentration-time curve (AUC)…
Worked on STAVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children
Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children